Hydrochloride methanol → 1-(6-(1,4-Diazepan-1-yl)pyridin-2-yl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine
反応式
[NH:1]1[CH:5]=[C:4]([C:6]2[N:11]=[CH:10][C:9]3[CH:12]=[N:13][N:14]([C:15]4[N:20]=[C:19]([N:21]5[CH2:27][CH2:26][CH2:25][N:24](C([O-])=O)[CH2:23][CH2:22]5)[CH:18]=[CH:17][CH:16]=4)[C:8]=3[CH:7]=2)[CH:3]=[N:2]1.Cl.[CH3:32]O>>[N:21]1([C:19]2[N:20]=[C:15]([N:14]3[C:8]4[CH:7]=[C:6]([C:4]5[CH:3]=[N:2][N:1]([CH3:32])[CH:5]=5)[N:11]=[CH:10][C:9]=4[CH:12]=[N:13]3)[CH:16]=[CH:17][CH:18]=2)[CH2:27][CH2:26][CH2:25][NH:24][CH2:23][CH2:22]1参加物
3
実験手順
A solution of 4-(6-(6-(1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepane-1-carboxylate (440 mg, 0.93 mmol) in a solution of HCl/MeOH (2M, 10 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure. The crude was purified by reverse phase preparative HPLC to afford 224 as a yellow solid (180 mg, 51.8%). 1H NMR (500 MHz, DMSO-d6) δ (ppm) 9.095-9.098 (d, J=1.5 Hz, 1H), 8.61 (s, 1H), 8.45 (s, 1H), 8.14 (s, 1H), 7.87 (s, 1H), 7.64-7.69 (t, J=13.5 Hz, 1H), 7.13-7.16 (d, J=12.5 Hz, 1H), 6.55-6.58 (d, J=14.5 Hz, 1H), 3.90-3.91 (d, J=8 Hz, 3H), 3.78-3.87 (m, 6H), 3.01-3.05 (t, J=13 Hz, 2H), 1.87-1.91 (m, 2H); MS (ESI) m/z: 375 [M+H]+.